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Hormone Response to Repeated 
Electroconvulsive Therapy: 
Effects of Naloxone 
Roger F. Haskett, Athanasios P. Zis, and A. Ariav Albala 
Plasma prolactin (PRL ), cortisol, and growth hormone (GH) were measured before, and 
at 15-min intervals for 1 hr after, electroconvulsive therapy (ECT). This was repeated 
over a series of 6 consecutive treatments for each of 12 depressed drug-free inpatients. 
Patients received naloxone, 2 mg or 20 mg, by intravenous infusion before the third and 
fifth treatment. ECT was consistently followed by a release of PRL and cortisol, although 
two patterns of PRL response could be distinguished. In eight patients, the PRL response 
did not change significantly with repeated ECT, whereas in four patients, the plasma 
PRL increased tenfoM after the first treatment and decreased after each successive treat- 
ment. The GH level varied widely, with no evidence of a reliable response to ECT. Opiate 
receptor blockade with low- or high-dose naloxone did not alter the release of PRL or 
cortisol after ECT. These findings demonstrate a reliable PRL and cortisol response to 
ECT, but do not support a role for endogenous opiates in these hormonal changes. 
Introduction 
Plasma levels of prolactin (PRL) increase after the administration of electroeonvulsive 
therapy (ECT) (Ohman et al. 1976; O'Dea et al. 1978; Skrabanek et al. 1981; Arato and 
Bagdy 1982; Balldin 1982; Whalley et al. 1982). Several observations suggest that this 
PRL release is the result of the generalized seizure. Unmodified ECT (no anesthesia or 
muscle relaxant) produced a definite increase in PRL levels (Klimes et al. 1978), whereas 
simulated ECT (anesthesia without electrical stimulus) produced either a nonsignificant 
PRL increase (Arato et al. 1980) or a significantly smaller PRL increase than "real" ECT 
(Deakin et al. 1983). Elevated PRL levels have also been reported after spontaneous 
generalized seizures in patients suffering from epilepsy (Trimble 1978; Abbott et al. 
1980), whereas PRL release was not observed after partial, hysterical, or pseudo seizures 
(Collins et al. 1983). 
Identifying the mechanisms that mediate this hypothalamopituitary response to ECT 
might increase our understanding of the central neurotransmitter changes associated with 
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this treatment. Reports from several studies suggest that endogenous opiates are involved 
in certain PRL responses. PRL is released after the administration of morphine (Tolis et 
al. 1975; Extein et al. 1980; Zis et al. in press) and 13-endorphin (Catlin et al. 1980), 
and the PRL response to an enkephalin analog is attenuated by prior infusion of the opiate 
antagonist, naloxone (Stubbs et al. 1978). Naloxone blocks the PRL response to physical 
exercise (Moretti et al. 1983) and gynecological surgery (Corenblum and Taylor 1981), 
but does not appear to significantly influence PRL release in the tonic/basal state (Volavka 
et al. 1980; Cohen et al. 1983) or following hypoglycemia (Grossman et al. 1981), sleep 
(Martin et al. 1979), and gastroscopy (Morley et al. 1980). Circulating levels of 13- 
endorphin are reported to increase after ECT (Emrich et al. 1979; Alexopoulos et al. 
1983; Misiaszek et al. 1984), although no relationship has been demonstrated between 
these endogenous opiates and neuroendocrine response to ECT. There has, however, 
been some speculation that the release of peptides in the hypothalamus-pituitary system 
may be related to the therapeutic effects of ECT (Fink 1982). 
We report the effect of ECT on PRL, cortisol, and growth hormone (GH), with repeated 
measurements over a series of six consecutive treatments. The present study also examines 
the hypothesis that the ECT-induced PRL response was a manifestation of endogenous 
opiate release by observing the effects of pretreatment with the opiate antagonist, nal- 
o x o n e .  
M e t h o d s  
Twelve patients, nine women and three men, who met the Research Diagnostic Criteria 
(Spitzer et al. 1978) for either major depressive disorder--endogenous subtype or schizo- 
affective disorder-depressed type were included in this study. Their mean age was 
42.7 years (range 30-71) and the mean pretreatment score on the 17-item Hamilton 
Depression Rating Scale (HDRS) (Hamilton 1960) was 24.3 (range 13-36). All 
patients were free of psychotropic medication for at least 5 days prior to ECT and 
for the duration of the study. Each patient, at a separate interview, had consented 
to his or her treating psychiatrist 's recommendation for ECT before informed con- 
sent to this study was obtained. 
The first six ECT treatments, administered three times per week, were included in the 
experimental protocol. The treating psychiatrist determined the total number of treatments 
for each patient according to clinical response (mean 10.3, range 6-16). All patients had 
fasted since midnight, and the intravenous catheter used for administration of the anesthetic 
agents was inserted into the patient's forearm approximately 1 hr before treatment and 
was kept patent with heparinized saline. Patients were taken to the treatment room 
approximately 30 min before ECT and remained there for 1 hr after completion of the 
treatment. All treatments were given between 8:00 and 9:30 AM. 
Standard anesthetic procedure included a premedication with glycopyrrolate (0-0.5 
mg), which was administered approximately 1 hr before the treatment. Anesthesia was 
induced with methohexital sodium (40-100 mg), muscle relaxation was obtained with 
succinylcholine chloride (50-80 mg), and oxygenation was provided by assisted venti- 
lation throughout the procedure. ECT was administered using a Medcraft machine with 
bitemporal electrode placement. Electrical stimulus ranged from 120 to 160 V for 0.4--1.0 
sec. Seizure duration was monitored in one limb that was not exposed to the muscle 
relaxant due to the prior inflation of a sphygrnomanometer to suprasystolic pressures. 
Blood samples were obtained through a three-way tap in the intravenous line after the 
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first 1-2 ml of blood were discarded. Blood was collected in heparinized tubes, packed 
in ice, centrifuged within 30 min, and stored at -20°C.  Samples were drawn before 
anesthesia, after anesthesia but before the electrical stimulus, and 15, 30, 45, and 60 
min after the generalized seizure. All plasma samples from a single subject were analyzed 
in the same assay. Before treatments 3 and 5, naloxone was administered through the 
intravenous line after the first blood sample and immediately preceding the anesthesia. 
Subjects 1 through 8 received 2 mg naloxone over 1 min, and subjects 9 through 12 
received 20 mg naloxone over 5-10 min. 
Plasma PRL was measured by an established double-antibody radioimmunoassay tech- 
nique (Sinha et al. 1973). The antibody and primary standard were kindly donated by 
the NIH National Pituitary Agency and prepared by Dr. A. F. Parlow of Harbor General 
Hospital, Torrance, CA. The linear range of the assay was 0.5-200.0 ng/ml. Samples 
above 200 ng/ml were serially diluted until they fell within the assay range. Total plasma 
corticoids ("cortisol") were measured by the transcortin method of Murphy (1967). GH 
measurement utilized a radioimmunoassay supplied by Serono. 
Resu l t s  
Hormone Release after Successive ECT Treatment 
A definite increase in plasma PRL and cortisol occurred after each ECT treatment (Figures 
1 and 2). The peak levels of PRL and cortisol occurred 15 and 30 min, respectively, 
after the induced seizure. GH responses were extremely variable, and the mean plasma 
levels did not change significantly after ECT (Figure 3). The mean baseline levels of 
PRL and cortisol did not vary significantly between treatment days (F = 0.45, df = 5,55, 
p = 0.81 and F = 0.17, df = 5,55, p = 0.97, respectively). 
The mean PRL response (peak minus baseline, APRL) after each of the six treatments 
decreased from 94.0 ng/ml after treatment 1 to 53.6 I~g/ml after treatment 6 (Table 1). 
Inspection of the data, however, suggests that this change in APRL occurred predominantly 
in four subjects (1, 5, 6, and 7), with an unusually large APRL after treatment 1 (range 
116.6-292.0 ng/ml). Figure 4 shows the APRL after each treatment for two subgroups 
of patients selected according to whether the APRL after treatment 1 was greater (N = 4) 
or less (N = 8) than the mean APRL for all patients after that treatment. We performed 
a two-way analysis of variance with treatment number as a repeated measures factor and 
APRL as a grouping factor. The PRL response showed a significant effect for Group 
(F = 24.22, df = 1,10, p = 0.0006) and Treatment Number (F = 14.92, df = 5,50, 
p = 0.0000). Trend analysis of the Treatment Number main effect revealed a significant 
linear component (F = 34.56, df = 1,10, p = 0.0002), which reflected the overall 
change (decrease) in mean APRL with successive treatments. The presence of a significant 
quadratic component (F = 8.32, df = 1,10, p = 0.0163) reflected the much larger 
decreases in mean APRL between treatments 1, 2, and 3 than between treatment 3, 4, 
5, and 6. The Group by Treatment Number interaction effect was significant (F = 13.38, 
df = 5,50; p = 0.0000), and trend analysis revealed a significant linear component 
(F = 34.85, df = 1,10; p = 0.0002). This reflected the different between-treatment 
change in mean APRL for the four patients with large initial APRL values compared with 
the other eight patients with lower APRL values. Baseline PRL levels were not signifi- 
cantly different between the two subgroups of patients. The mean cortisol response (peak 
minus baseline, Acortisol) after each treatment did not change significantly between 
treatments (F = 1.67, df = 5,55; p = 0.18). 
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Figure 1. Plasma pmlactin concentrations (mean and sin4) before and 15, 30, 45, and 60 rain after 
first six treatments with ECT (N = 12). 
Effect of Naloxone Pretreatment 
Figures 5 and 6 show the results of naloxone pretreatment on the PRL and cortisol response 
after ECT. We performed a three-way analysis of variance with pretreatment drug (nal- 
oxone versus control) and order (treatments 3 and 4 versus 5 and 6) as repeated measures 
factors and naloxone dosage (2 mg versus 20 rag) as a between-groups factor. This 
analysis excluded treatments 1 and 2 because of the variable change in APRL described 
above and compared treatments 3 and 5 (naloxone pretreatment) with treatments 4 and 
6 (control). There were no significant effects for naloxone pretreatment, treatment order, 
or naloxone dosage on either PRL or cortisol response. 
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Figure 2. Plasma cortisol concentrations (mean and SEM) before and 15, 30, 45, and 60 rain after 
first six treatments with ECT (N = 12). 
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Figure 3. Plasma growth hormone concentrations (mean and SEM) before and 15, 30, 45, and 60 
min after first six treatments with ECT (N = 12). 
Relationship between Hormone Release and Treatment Response 
Three patients had an adequate clinical response to 6 treatments with ECT, and their 
HDRS scores decreased to 1, 2, and 4. The remaining 9 patients required an additional 
1-10 treatments before the course of ECT was completed. When patients were grouped 
according to whether their APRL after treatment 1 was greater (N = 4) or less (N = 8) 
than the mean, there was no significant difference between the mean pretreatment HDRS 
scores (25.3 and 23.9, respectively) or mean numbers of ECT treatments received (8.5 
and 9.75, respectively). 
Table 1. Prolactin Response after ECT (Peak Minus Baseline, ng/ml) 
Treatment number 
1 2 3 4 5 6 Mean 
Patient 
1 292.0= 207.1 69.4 114.7 92.9 81.0 142.8 
2 52.4 43.3 40.5 51.1 46.9 31.7 44.3 
3 53.0 33.5 33.0 18.4 32.4 63.9 39.0 
4 41.3 35.8 26.1 24.3 19.4 57.6 34.1 
5 116.6 ° 117.1 76.4 80.5 65.9 51.5 84.7 
6 191.4 ° 124.9 102.6 99.0 86.0 75.3 113.2 
7 147.1 = 105.1 124.2 63.5 60.3 48.5 91.4 
8 71.6 88.0 72.5 67.7 99.8 97.1 82.8 
9 54.4 42.7 50.0 42.6 57.7 46.6 49.0 
10 31.4 45.5 46.5 45.6 41.0 51.1 43.5 
11 48.8 35.2 36.3 29.8 32.1 31.2 35.6 
12 27.6 14.4 12.7 6.4 12.4 8.3 13.6 
Mean 94.0 74.4 57.5 53.6 53.9 53.6 64.5 
=Subjects with APRL after treatment 1 greater than mean. 
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Figure 4. Prolactin response (mean and SEM) after first six treatments with ECT. There were four 
patients with APRL aRer treatment 1 that was greater than the group mean (shaded bars) and eight 
patients with APRL after treatment 1 less than the group mean (unshaded bars). 
Discussion 
Our data indicate that ECT is consistently followed by a release of PRL, which is in 
agreement with previous reports. We also examined this phenomenon over repeated 
treatments. Although the mean APRL for the total group decreased across the course of 
treatment, two patterns of response could be distinguished. In eight patients (67%), the 
magnitude of the APRL was six times the baseline value and did not change significantly 
with repeated ECT treatment. However, in four patients (33%), the plasma PRL increased 
tenfold after the first treatment, and APRL decreased after each successive treatment. By 
the sixth treatment, the APRL approached the mean value noted after each treatment in 
the other eight patients. The absence of any significant clinical differences between 
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Figure 5. Prolactin and cortisol responses (mean and SEM) after ECT treatments 3-6. Patients 
received naloxone, 2 rag, before ECT treatments 3 and 5 (N = 8). 
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Figure 6. Prolactin and cortisol responses (mean and SEM) after ECT treatments 3-6. Patients 
received naloxone, 20 rag, before ECT treatments 3 and 5 (N = 4). 
these two subgroups of patients (mean pretreatment HDRS score and total number of 
treatments given in the course) suggests that the change in APRL is not related to the 
severity of illness or the speed of the clinical response to ECT. 
The demonstration of these two disparate patterns of PRL response may provide an 
explanation for the apparent disagreement between reports that found a decrease in APRL 
over a course of treatments (Meco et al. 1978; Deakin et al. 1983) and those that found 
no significant variation (Skrabanek et al. 1981; Whalley et al. 1982; Linnoila et al. 1984). 
The etiology of this variability in PRL response between individuals, however, is not 
readily apparent. PRL secretion can be influenced by a wide variety of factors, for 
example, circulating estrogens have a stimulatory effect on PRL secretion and increase 
the responsivity of PRL to various stimuli (Frantz 1978). It is notable that all four patients 
with large APRL after ECT were women, mean age 41.3 years, whereas three of eight 
patients with lower and constant APRL after ECT were men and the mean age of the 
remaining five women was 54.4 years. All patients in this study were drug-free, and none 
had been recently withdrawn from neurolepties or other drugs known to alter PRL se- 
cretion. Further examination of this variability in the pattern of PRL response is needed 
to determine whether it is an epipbenomenon, e.g., related to sex and estrogen levels, 
or a marker that distinguishes a valid subeategory of affective disorder. 
The release of cortisol after ECT in these patients was also a stable and relatively 
uniform response that did not change significantly with repeated treatment. This agrees 
with most studies that have reported changes in cortisol or cortieotropin (ACTH) after 
ECT (Elithorn et al. 1969; Allen et al. 1974; Delitala et al. 1977; Deakin et al. 1983). 
Whalley et al. (1982) were unable to demonstrate a eortisol response after ECT, but this 
discrepancy may have resulted from their failure to sample for longer than 6 min after 
the seizure. Although we did not measure levels of ACITI, it is likely that the observed 
eortisol response was preceded by an acute release of ACTH (Ylikorkala et al. 1976). 
As there is evidence that ~-endorphin and ACTH are secreted concomitantly (Guillemin 
et al. 1977), we believe that our findings are consistent with the previous reports of an 
ECT-induced release of these pituitary hormones. The GH level in these patients varied 
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widely. Most studies have been unable to demonstrate a reliable GH response after ECT 
(Ryan et al. 1970; Allen et al. 1974; Delitala et al. 1977; Arato et al. 1980; Whalley et 
al. 1982; Deakin et al. 1983). Vigas et al. (1975) and Skrabanek et al. (1981) did report 
a GH response, although the patients in the first study received unmodified ECT. 
The present data suggest that opiate receptor blockade does not alter the release of 
PRL and cortisol after ECT. Naloxone is a potent and specific opiate antagonist that 
rapidly crosses the blood--brain barrier. Maximum concentration of naloxone in the central 
nervous system (CNS) occurs within minutes of infusion and the plasma half-life is 
approximately 60 min (Fishman et al. 1973; Berkowitz et al. 1975). We administered 
intravenous naloxone infusions in low (2 mg, 0.02-0.05 mg/kg) and high (20 mg, 0.20--0.42 
mg/kg) doses because there is evidence for the existence of several opiate receptor subtypes 
that have differing profiles of response to opiate agonists and antagonists (Lord et al. 
1977; Chang and Cuatrecasas 1979). We expected the low dose of naloxone to abolish 
effects that were mediated by the p,-receptors, as these have a high affinity for naloxone, 
whereas higher doses are needed to also block the relatively naloxone-insensitive ~- 
receptors. It remains possible that even higher doses of naloxone could affect the ECT- 
induced PRL response, although it has been suggested that 16 mg naloxone produces 
maximal blockade of endogenous opiate tone in the hypothalamic-pituitary-adrenal axis 
(Grossman et al. 1982). In addition, Cohen et al. (1983) failed to show a naloxone dose- 
dependent effect on PRL secretion with naloxone doses up to 4 mg/kg. Although the 
administration of naloxone stimulates basal ACTH and cortisol secretion in normals 
(Volavka et al. 1980; Judd et al. 1981) and naloxone (10 mg) has been reported to enhance 
the cortisol response to gastroscopy (Morley et al. 1980), we found no difference in the 
cortisol response to ECT after naloxone. 
This study established the reliability and consistency of the PRL and hypotha- 
lamic-pituitary-adrenocortical (HPA) axis responses to ECT, especially after treatment 
3. PRL secretion and HPA axis function are influenced by multiple neurotransmitter 
systems, and these aspects of the neuroendocrine response to ECT deserve further study 
with other pharmacological probes. Recent evidence that exogenous opiates stimulate 
PRL release but inhibit cortisol secretion (Zis et al. in press) makes it less likely that 
endogenous opiates are responsible for these ECT-associated hormonal changes. The 
serotonergic system, however, may be of particular interest, as it has been demonstrated 
that serotonergic agonists can have a stimulatory effect on both PRL and cortisol release 
(see reviews by Checkley, 1980, and Reichlin, 1981). Systematic examination of these 
phenomena may eventually lead to clarification of the neurochemical events accompanying 
ECT. 
The authors thank Patricia Nelson, R.N., James Ritchie, M.S., and Kathleen F. Johnson, B.A., for their 
invaluable assistance with this study. 
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